Business Description
![Pfizer Inc Pfizer Inc logo](https://static.gurufocus.com/logos/0C00000C7U.png?14)
Pfizer Inc
NAICS : 325412
SIC : 2834
ISIN : US7170811035
Share Class Description:
MEX:PFE: Ordinary SharesCompare
Compare
Traded in other countries / regions
PFE.USA0Q1N.UKPFE.CanadaPFE.GermanyPFE.ArgentinaPFIZ34.BrazilPFE.Mexico1PFE.ItalyPFE.PeruPFE.ChilePFE.AustriaPFE_KZ.KazakhstanPFE.BulgariaPFE.UkrainePFEBC.Belgium IPO Date
1944-01-17Description
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.17 | |||||
Equity-to-Asset | 0.42 | |||||
Debt-to-Equity | 0.75 | |||||
Debt-to-EBITDA | 9.25 | |||||
Interest Coverage | 0.44 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.78 | |||||
Beneish M-Score | -2.48 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.9 | |||||
3-Year EBITDA Growth Rate | -10.4 | |||||
3-Year EPS without NRI Growth Rate | -6.1 | |||||
3-Year FCF Growth Rate | -26.8 | |||||
3-Year Book Growth Rate | 11.5 | |||||
Future 3-5Y EPS without NRI Growth Rate | 14.03 | |||||
Future 3-5Y Total Revenue Growth Rate | 2.6 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 60.96 | |||||
9-Day RSI | 57.23 | |||||
14-Day RSI | 57.14 | |||||
6-1 Month Momentum % | -3.04 | |||||
12-1 Month Momentum % | -23.38 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.05 | |||||
Quick Ratio | 0.78 | |||||
Cash Ratio | 0.29 | |||||
Days Inventory | 159.2 | |||||
Days Sales Outstanding | 73.92 | |||||
Days Payable | 92.91 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 5.65 | |||||
Dividend Payout Ratio | 1.17 | |||||
3-Year Dividend Growth Rate | 2.6 | |||||
Forward Dividend Yield % | 5.94 | |||||
5-Year Yield-on-Cost % | 6.81 | |||||
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | -13.61 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 57.44 | |||||
Operating Margin % | 2.16 | |||||
Net Margin % | -0.56 | |||||
FCF Margin % | 9.31 | |||||
ROE % | -0.32 | |||||
ROA % | -0.14 | |||||
ROIC % | 0.09 | |||||
ROC (Joel Greenblatt) % | 4.94 | |||||
ROCE % | 0.5 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 12.48 | |||||
PE Ratio without NRI | 19.7 | |||||
Shiller PE Ratio | 10.09 | |||||
Price-to-Owner-Earnings | 297.66 | |||||
PEG Ratio | 2.43 | |||||
PS Ratio | 2.88 | |||||
PB Ratio | 1.72 | |||||
Price-to-Free-Cash-Flow | 30.78 | |||||
Price-to-Operating-Cash-Flow | 18.41 | |||||
EV-to-EBIT | 241.94 | |||||
EV-to-Forward-EBIT | 12.7 | |||||
EV-to-EBITDA | 28.99 | |||||
EV-to-Forward-EBITDA | 10.51 | |||||
EV-to-Revenue | 3.91 | |||||
EV-to-Forward-Revenue | 3.6 | |||||
EV-to-FCF | 42.17 | |||||
Price-to-Projected-FCF | 0.52 | |||||
Price-to-Median-PS-Value | 0.72 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.68 | |||||
Earnings Yield (Greenblatt) % | 0.41 | |||||
FCF Yield % | 3.22 | |||||
Forward Rate of Return (Yacktman) % | 21.78 |